http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-102018004537-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d71f4d06c9a84c3b0d6f69d842a84175 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-04 |
| filingDate | 2018-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44161c7b784129c58b62a846052f0ee5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15b159da4c32b7932a98534ae5a3fd0a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5adce1164099df37f3846aceff33bb1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7fcbf7ce72bcfaa6d597cbd54080a88e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77f2275a9f9ce3d2ed09b701121ef6a9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_37448b6468d10b46802ba9e213d6cff5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce19b78bf2f557b57ca67b3f7b5e6aa6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9c1eaa1f137393773e6f93b092d4ae2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be934b865fe9e3f7a8f2fc2c46d59461 |
| publicationDate | 2019-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-102018004537-A2 |
| titleOfInvention | 1-METHYL-3- (PHENILSELENYL) -1H-INDOL ANTI-DIABETOGENIC AND ANTIDEPRESSIVE MOLECULE |
| abstract | the aforementioned patent application is included in the international classification of patents within the human needs section, designated by letter a and specifically subsection 61, which is related to medical or veterinary science; hygiene. It is also classified under subclass p, where patents are related to the specific therapeutic activity of chemical compounds or medicinal preparations, specifically in subgroup 3/10 and 25/24, where antidiabetic and antidepressant drugs fall, respectively. The present patent relates to the use of the 1-methyl-3- (phenylselenyl) -1h-indole molecule in the treatment of type 1 diabetes mellitus and major depression, so that patients have effective treatment for these conditions and use only one medication. The objective is to reduce the time of onset of therapeutic action (14 days), minimal adverse effects of the drug, and use of low doses, aiming at improving patients' quality of life and treatment effectiveness. |
| priorityDate | 2018-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 173.